3:33 PM
Sep 11, 2017
 |  BC Extra  |  Clinical News

Shire’s subcutaneous HAE candidate meets in Phase III

Shire plc (LSE:SHP; NASDAQ:SHPG) said SHP616 met the primary endpoint in the Phase III SAHARA trial to treat symptomatic hereditary angioedema in patients ages 12 and older. SHP616 is a lower-dose volume, subcutaneous liquid formulation of IV Cinryze, the company's marketed complement 1 (C1) esterase inhibitor.

In the 75-patient trial, 2,000 IU SHP616 given every three to four days as...

Read the full 299 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >